Joshua Shofaro

The Low Molecular Weight Hyaluronan Fragment HA35 Serves as a Dual Antagonist of Pain-Related Calcium Channels TRPV1 and TRPA1

Xinyue Ma, Joshua Shofaro, Xiaoxiao Jia, Zhaohui Ma & Mizhou Hui · Journal of Pharmaceutical Research International · 2025

Background: Pain, especially chronic pain, remains a major health challenge worldwide. Transient receptor potential (TRP) channels, particularly TRPV1 and TRPA1, play crucial roles in pain perception. Hyaluronic acid (HA), whose bioactivity varies by molecular weight, has shown p...

Open access Research Article 10.9734/jpri/2025/v37i67702

Rapid Lymphatic Absorption of Orally Administered Low-Molecular-Weight Hyaluronic Acid: A Pathway to the Bloodstream via Mesenteric Nodes

Khandmaa Dashnyam, Joshua Shofaro, Jessica Hui, Xiaoxiao Jia & Mizhou Hui · Journal of Pharmaceutical Research International · 2025

Background: The 35 kDa low-molecular-weight hyaluronic acid (HA35) injection has shown efficacy in alleviating various types of pain, reducing inflammation and edema, and exhibiting potential in lipolysis and cosmetic applications. Compared to injectable forms, oral administratio...

Open access Research Article 10.9734/jpri/2025/v37i57698